Patents Assigned to IMCHECK THERAPEUTICS SAS
  • Anti-BTN3A antibodies and their use in treating cancer or infectious disorders
    Patent number: 11945871
    Abstract: The present invention relates to humanized antibodies that specifically bind to human BTN3A and their use in treating cancer and infectious disorders.
    Type: Grant
    Filed: June 1, 2023
    Date of Patent: April 2, 2024
    Assignees: IMCHECK THERAPEUTICS SAS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE AIX MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS
    Inventors: Alemseged Truneh, Daniel Olive, Christine Pasero, Aude De Gassart
  • Antibodies having specificity for BTN2 and uses thereof
    Patent number: 11572409
    Abstract: The present invention relates to antibodies having specificity for BTN2 and uses thereof, in particular for the treatment of cancer.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: February 7, 2023
    Assignees: IMCHECK THERAPEUTICS SAS, INSERM, INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITÉ D'AIX-MARSEILLE, CNRS
    Inventors: Daniel Olive, Christine Pasero